2023-09-12 17:36:00
CAMBRIDGE, Mass. –
ReNAgade Therapeutics, a company unlocking the limitless potential of RNA medicines, today announced the appointment of Laurie Stelzer as Chief Financial Officer. Ms. Stelzer most recently served as Chief Financial Officer of Mirati Therapeutics and brings over 25 years of experience to further strengthen ReNAgade’s leadership team.
“Laurie is a seasoned executive with extensive experience in the pharmaceutical and biotech industries, whose work spans corporate finance and strategy, business development and helping to build key capabilities needed to generate long-term value for stakeholders “I have worked with Laurie for over 20 years and am thrilled to welcome her to our leadership team as our first Chief Financial Officer at a time when we expand our scientific expertise and our company growth.”
“By advancing its industry-leading platform, ReNAgade is poised to bring RNA medicines to previously inaccessible tissues and cells in the body,” said Ms. Stelzer. “I am very pleased regarding the opportunity to help shape and support the growth of ReNAgade and thus the progress in the entire field of RNA medicines.”
Ms. Stelzer has more than 25 years of experience supporting the financial functions of biopharma companies and most recently served as CFO for Mirati Therapeutics. She was previously CFO of Arena Pharmaceuticals, where she helped lead the company’s growth through its acquisition by Pfizer for $6.7 billion. She also served as CFO for Halozyme Therapeutics, where she was active in finance, IT, business development and project management. She has also held senior management positions at Shire, including Senior Vice President of Finance, Division CFO for the Regenerative Medicine Division and Head of Investor Relations. She began her biotech career at Amgen, where she spent 15 years in positions of increasing responsibility, with various roles in finance, global commercialization, treasury and international/growth markets. Laurie earned her BS in Accounting from Arizona State University and her MBA from the Anderson School of Management at the University of California, Los Angeles.
About ReNAgade Therapeutics
ReNAgade’s mission is to unlock the potential of RNA medicines to treat diseases anywhere in the body. We combine our novel RNA delivery platform with a comprehensive RNA platform, enabling a complete RNA system for coding, editing and gene insertion for new drug development.
We are assembling a team with deep RNA expertise and delivery expertise to develop RNA medicines that enable true paradigm shifts.
ReNAgade Therapeutics—RNA Without Limits
For more information regarding the company, its technologies and leadership, please visit www.renagadetx.com.
The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. Therefore, compare translations with the original language version of the publication.
View original version on businesswire.com:
Quelle: Business Wire
1694583080
#ReNAgade #Therapeutics #Appoints #Laurie #Stelzer #Chief #Financial #Officer
